Title
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Funding Source
National Institutes of Health
Grant Number
2G12MD007595, 1U54GM104940
Department
Department of Chemistry
Document Type
Article
Publication Date
3-1-2015
Abstract
Histone dacetylases (HDACs) are a group of enzymes that remove acetyl groups from histones and regulate expression of tumor suppressor genes. They are implicated in many human diseases, especially cancer, making them a promising therapeutic target for treatment of the latter by developing a wide variety of inhibitors. HDAC inhibitors interfere with HDAC activity and regulate biological events, such as cell cycle, differentiation and apoptosis in cancer cells. As a result, HDAC inhibitor-based therapies have gained much attention for cancer treatment. To date, the FDA has approved three HDAC inhibitors for cutaneous/peripheral T-cell lymphoma and many more HDAC inhibitors are in different stages of clinical development for the treatment of hematological malignancies as well as solid tumors. In the intensifying efforts to discover new, hopefully more therapeutically efficacious HDAC inhibitors, molecular modeling-based rational drug design has played an important role in identifying potential inhibitors that vary in molecular structures and properties. In this review, we summarize four major structural classes of HDAC inhibitors that are in clinical trials and different computer modeling tools available for their structural modifications as a guide to discover additional HDAC inhibitors with greater therapeutic utility.
Recommended Citation
Mottamal, M; Zheng, Shilong; Huang, T L.; and Wang, Guangdi, "Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents" (2015). Faculty and Staff Publications. 144.
https://digitalcommons.xula.edu/fac_pub/144
Comments
DOI: 10.3390/molecules20033898
PubMed ID: 25738536
This work was supported by the National Institute of Minority Health and Disparities of the National Institute of Health (NIMHD-NIH) through Grant number 2G12MD007595, the National Institute of General Medical Sciences of the National Institute of Health (NIGMS-NIH) through grant number 1U54GM104940 and in part by Louisiana Cancer Research Consortium (LCRC).